nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—CYP1A1—Progesterone—uterine cancer	0.198	0.294	CbGbCtD
Albendazole—CYP1A2—Progesterone—uterine cancer	0.0884	0.131	CbGbCtD
Albendazole—ABCB1—Progesterone—uterine cancer	0.0773	0.115	CbGbCtD
Albendazole—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0699	0.104	CbGbCtD
Albendazole—ABCB1—Dactinomycin—uterine cancer	0.0613	0.091	CbGbCtD
Albendazole—CYP3A4—Progesterone—uterine cancer	0.0463	0.0687	CbGbCtD
Albendazole—CYP1A2—Etoposide—uterine cancer	0.0395	0.0587	CbGbCtD
Albendazole—ABCB1—Etoposide—uterine cancer	0.0346	0.0513	CbGbCtD
Albendazole—ABCB1—Doxorubicin—uterine cancer	0.0236	0.035	CbGbCtD
Albendazole—CYP3A4—Etoposide—uterine cancer	0.0207	0.0308	CbGbCtD
Albendazole—TUBA1A—oviduct—uterine cancer	0.017	0.132	CbGeAlD
Albendazole—CYP3A4—Doxorubicin—uterine cancer	0.0141	0.021	CbGbCtD
Albendazole—TUBB4B—oviduct—uterine cancer	0.0113	0.0881	CbGeAlD
Albendazole—Alopecia reversible—Etoposide—uterine cancer	0.00766	0.0601	CcSEcCtD
Albendazole—TUBA1A—myometrium—uterine cancer	0.00543	0.0423	CbGeAlD
Albendazole—Alopecia reversible—Epirubicin—uterine cancer	0.0043	0.0337	CcSEcCtD
Albendazole—TUBA1A—epithelium—uterine cancer	0.00426	0.0332	CbGeAlD
Albendazole—TUBA1A—uterine cervix—uterine cancer	0.00423	0.0329	CbGeAlD
Albendazole—TUBA1A—smooth muscle tissue—uterine cancer	0.00411	0.032	CbGeAlD
Albendazole—TUBA1A—decidua—uterine cancer	0.00403	0.0314	CbGeAlD
Albendazole—Alopecia reversible—Doxorubicin—uterine cancer	0.00397	0.0311	CcSEcCtD
Albendazole—TUBA1A—renal system—uterine cancer	0.00396	0.0308	CbGeAlD
Albendazole—TUBA1A—endometrium—uterine cancer	0.00382	0.0298	CbGeAlD
Albendazole—TUBA1A—mammalian vulva—uterine cancer	0.0037	0.0288	CbGeAlD
Albendazole—TUBB4B—myometrium—uterine cancer	0.00362	0.0282	CbGeAlD
Albendazole—TUBA1A—uterus—uterine cancer	0.00352	0.0274	CbGeAlD
Albendazole—TUBA1A—female reproductive system—uterine cancer	0.00317	0.0247	CbGeAlD
Albendazole—TUBA1A—female gonad—uterine cancer	0.00288	0.0224	CbGeAlD
Albendazole—TUBA1A—vagina—uterine cancer	0.00286	0.0223	CbGeAlD
Albendazole—TUBB4B—uterine cervix—uterine cancer	0.00282	0.0219	CbGeAlD
Albendazole—TUBB4B—smooth muscle tissue—uterine cancer	0.00274	0.0213	CbGeAlD
Albendazole—TUBB4B—decidua—uterine cancer	0.00268	0.0209	CbGeAlD
Albendazole—TUBB4B—renal system—uterine cancer	0.00264	0.0205	CbGeAlD
Albendazole—TUBB4B—endometrium—uterine cancer	0.00255	0.0198	CbGeAlD
Albendazole—TUBB4B—mammalian vulva—uterine cancer	0.00247	0.0192	CbGeAlD
Albendazole—TUBB4B—uterus—uterine cancer	0.00235	0.0183	CbGeAlD
Albendazole—Liver function test abnormal—Progesterone—uterine cancer	0.00228	0.0179	CcSEcCtD
Albendazole—Aplastic anaemia—Dactinomycin—uterine cancer	0.00226	0.0177	CcSEcCtD
Albendazole—TUBB4B—female reproductive system—uterine cancer	0.00211	0.0164	CbGeAlD
Albendazole—TUBB4B—female gonad—uterine cancer	0.00192	0.015	CbGeAlD
Albendazole—TUBB4B—vagina—uterine cancer	0.00191	0.0149	CbGeAlD
Albendazole—TUBA1A—lymph node—uterine cancer	0.00185	0.0144	CbGeAlD
Albendazole—Body temperature increased—Carboplatin—uterine cancer	0.00183	0.0143	CcSEcCtD
Albendazole—Hepatobiliary disease—Progesterone—uterine cancer	0.0018	0.0141	CcSEcCtD
Albendazole—Hepatitis—Progesterone—uterine cancer	0.00171	0.0134	CcSEcCtD
Albendazole—Urinary tract disorder—Progesterone—uterine cancer	0.00169	0.0132	CcSEcCtD
Albendazole—Urethral disorder—Progesterone—uterine cancer	0.00167	0.0131	CcSEcCtD
Albendazole—Hepatobiliary disease—Medroxyprogesterone Acetate—uterine cancer	0.00163	0.0128	CcSEcCtD
Albendazole—Erythema multiforme—Progesterone—uterine cancer	0.00161	0.0127	CcSEcCtD
Albendazole—Liver function test abnormal—Dactinomycin—uterine cancer	0.00161	0.0126	CcSEcCtD
Albendazole—CYP1A1—epithelium—uterine cancer	0.00159	0.0124	CbGeAlD
Albendazole—CYP1A1—uterine cervix—uterine cancer	0.00158	0.0123	CbGeAlD
Albendazole—Hepatitis—Medroxyprogesterone Acetate—uterine cancer	0.00155	0.0121	CcSEcCtD
Albendazole—Immune system disorder—Progesterone—uterine cancer	0.00154	0.0121	CcSEcCtD
Albendazole—Urinary tract disorder—Medroxyprogesterone Acetate—uterine cancer	0.00153	0.012	CcSEcCtD
Albendazole—Urethral disorder—Medroxyprogesterone Acetate—uterine cancer	0.00152	0.0119	CcSEcCtD
Albendazole—Alopecia—Progesterone—uterine cancer	0.00151	0.0118	CcSEcCtD
Albendazole—CYP1A2—renal system—uterine cancer	0.0015	0.0116	CbGeAlD
Albendazole—CYP1A1—renal system—uterine cancer	0.00148	0.0115	CbGeAlD
Albendazole—Erythema multiforme—Medroxyprogesterone Acetate—uterine cancer	0.00146	0.0115	CcSEcCtD
Albendazole—Pancytopenia—Dactinomycin—uterine cancer	0.00143	0.0112	CcSEcCtD
Albendazole—Neutropenia—Dactinomycin—uterine cancer	0.00141	0.0111	CcSEcCtD
Albendazole—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.0014	0.011	CcSEcCtD
Albendazole—CYP1A1—mammalian vulva—uterine cancer	0.00138	0.0107	CbGeAlD
Albendazole—Alopecia—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.0107	CcSEcCtD
Albendazole—Vertigo—Progesterone—uterine cancer	0.00134	0.0105	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Dactinomycin—uterine cancer	0.00133	0.0104	CcSEcCtD
Albendazole—CYP1A1—uterus—uterine cancer	0.00132	0.0102	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Progesterone—uterine cancer	0.00126	0.00985	CcSEcCtD
Albendazole—Agranulocytosis—Dactinomycin—uterine cancer	0.00125	0.00983	CcSEcCtD
Albendazole—TUBB4B—lymph node—uterine cancer	0.00124	0.00962	CbGeAlD
Albendazole—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00121	0.00949	CcSEcCtD
Albendazole—Hepatitis—Dactinomycin—uterine cancer	0.00121	0.00946	CcSEcCtD
Albendazole—CYP1A1—female reproductive system—uterine cancer	0.00118	0.0092	CbGeAlD
Albendazole—Skin disorder—Progesterone—uterine cancer	0.00118	0.00924	CcSEcCtD
Albendazole—Erythema multiforme—Dactinomycin—uterine cancer	0.00114	0.00894	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Medroxyprogesterone Acetate—uterine cancer	0.00114	0.00893	CcSEcCtD
Albendazole—CYP3A4—renal system—uterine cancer	0.00108	0.00843	CbGeAlD
Albendazole—Thrombocytopenia—Medroxyprogesterone Acetate—uterine cancer	0.00108	0.00844	CcSEcCtD
Albendazole—CYP1A1—female gonad—uterine cancer	0.00108	0.00837	CbGeAlD
Albendazole—CYP1A1—vagina—uterine cancer	0.00107	0.00832	CbGeAlD
Albendazole—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.00107	0.00837	CcSEcCtD
Albendazole—Alopecia—Dactinomycin—uterine cancer	0.00107	0.00836	CcSEcCtD
Albendazole—ABCB1—myometrium—uterine cancer	0.00105	0.0082	CbGeAlD
Albendazole—Pancytopenia—Etoposide—uterine cancer	0.00104	0.00812	CcSEcCtD
Albendazole—Neutropenia—Etoposide—uterine cancer	0.00102	0.008	CcSEcCtD
Albendazole—Gastrointestinal pain—Progesterone—uterine cancer	0.000992	0.00778	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Etoposide—uterine cancer	0.000965	0.00756	CcSEcCtD
Albendazole—Urticaria—Progesterone—uterine cancer	0.000964	0.00755	CcSEcCtD
Albendazole—Abdominal pain—Progesterone—uterine cancer	0.000959	0.00752	CcSEcCtD
Albendazole—Body temperature increased—Progesterone—uterine cancer	0.000959	0.00752	CcSEcCtD
Albendazole—Leukopenia—Dactinomycin—uterine cancer	0.000941	0.00737	CcSEcCtD
Albendazole—Hepatobiliary disease—Etoposide—uterine cancer	0.00092	0.00721	CcSEcCtD
Albendazole—Aplastic anaemia—Epirubicin—uterine cancer	0.000916	0.00718	CcSEcCtD
Albendazole—Agranulocytosis—Etoposide—uterine cancer	0.000908	0.00712	CcSEcCtD
Albendazole—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000899	0.00705	CcSEcCtD
Albendazole—Hypersensitivity—Progesterone—uterine cancer	0.000894	0.00701	CcSEcCtD
Albendazole—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000873	0.00685	CcSEcCtD
Albendazole—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000869	0.00681	CcSEcCtD
Albendazole—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000869	0.00681	CcSEcCtD
Albendazole—CYP3A4—female reproductive system—uterine cancer	0.000867	0.00675	CbGeAlD
Albendazole—Urinary tract disorder—Etoposide—uterine cancer	0.000863	0.00676	CcSEcCtD
Albendazole—Urethral disorder—Etoposide—uterine cancer	0.000856	0.00671	CcSEcCtD
Albendazole—Aplastic anaemia—Doxorubicin—uterine cancer	0.000847	0.00664	CcSEcCtD
Albendazole—Thrombocytopenia—Dactinomycin—uterine cancer	0.00084	0.00658	CcSEcCtD
Albendazole—ABCB1—epithelium—uterine cancer	0.000827	0.00643	CbGeAlD
Albendazole—Erythema multiforme—Etoposide—uterine cancer	0.000826	0.00647	CcSEcCtD
Albendazole—ABCB1—uterine cervix—uterine cancer	0.00082	0.00638	CbGeAlD
Albendazole—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00081	0.00635	CcSEcCtD
Albendazole—Dizziness—Progesterone—uterine cancer	0.000802	0.00629	CcSEcCtD
Albendazole—Immune system disorder—Etoposide—uterine cancer	0.000789	0.00618	CcSEcCtD
Albendazole—ABCB1—decidua—uterine cancer	0.000781	0.00608	CbGeAlD
Albendazole—Alopecia—Etoposide—uterine cancer	0.000772	0.00605	CcSEcCtD
Albendazole—Vomiting—Progesterone—uterine cancer	0.000771	0.00605	CcSEcCtD
Albendazole—Renal failure acute—Epirubicin—uterine cancer	0.000767	0.00601	CcSEcCtD
Albendazole—ABCB1—renal system—uterine cancer	0.000767	0.00597	CbGeAlD
Albendazole—Rash—Progesterone—uterine cancer	0.000765	0.006	CcSEcCtD
Albendazole—Dermatitis—Progesterone—uterine cancer	0.000764	0.00599	CcSEcCtD
Albendazole—Headache—Progesterone—uterine cancer	0.00076	0.00596	CcSEcCtD
Albendazole—ABCB1—endometrium—uterine cancer	0.000741	0.00577	CbGeAlD
Albendazole—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000727	0.0057	CcSEcCtD
Albendazole—Nausea—Progesterone—uterine cancer	0.000721	0.00565	CcSEcCtD
Albendazole—ABCB1—mammalian vulva—uterine cancer	0.000717	0.00558	CbGeAlD
Albendazole—Renal failure acute—Doxorubicin—uterine cancer	0.000709	0.00556	CcSEcCtD
Albendazole—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000701	0.0055	CcSEcCtD
Albendazole—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000699	0.00548	CcSEcCtD
Albendazole—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000693	0.00543	CcSEcCtD
Albendazole—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000693	0.00543	CcSEcCtD
Albendazole—CYP1A1—lymph node—uterine cancer	0.000692	0.00538	CbGeAlD
Albendazole—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000689	0.0054	CcSEcCtD
Albendazole—Vertigo—Etoposide—uterine cancer	0.000683	0.00535	CcSEcCtD
Albendazole—ABCB1—uterus—uterine cancer	0.000683	0.00532	CbGeAlD
Albendazole—Leukopenia—Etoposide—uterine cancer	0.000681	0.00534	CcSEcCtD
Albendazole—Abdominal pain—Dactinomycin—uterine cancer	0.000678	0.00531	CcSEcCtD
Albendazole—Body temperature increased—Dactinomycin—uterine cancer	0.000678	0.00531	CcSEcCtD
Albendazole—Liver function test abnormal—Epirubicin—uterine cancer	0.000654	0.00512	CcSEcCtD
Albendazole—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000653	0.00512	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000643	0.00504	CcSEcCtD
Albendazole—Hypersensitivity—Dactinomycin—uterine cancer	0.000632	0.00495	CcSEcCtD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—YWHAE—uterine cancer	0.000621	0.00882	CbGpPWpGaD
Albendazole—ABCB1—female reproductive system—uterine cancer	0.000614	0.00478	CbGeAlD
Albendazole—Thrombocytopenia—Etoposide—uterine cancer	0.000608	0.00476	CcSEcCtD
Albendazole—Liver function test abnormal—Doxorubicin—uterine cancer	0.000605	0.00474	CcSEcCtD
Albendazole—Skin disorder—Etoposide—uterine cancer	0.000603	0.00472	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000583	0.00827	CbGpPWpGaD
Albendazole—Pancytopenia—Epirubicin—uterine cancer	0.000581	0.00455	CcSEcCtD
Albendazole—Neutropenia—Epirubicin—uterine cancer	0.000572	0.00448	CcSEcCtD
Albendazole—ABCB1—female gonad—uterine cancer	0.000559	0.00435	CbGeAlD
Albendazole—ABCB1—vagina—uterine cancer	0.000555	0.00432	CbGeAlD
Albendazole—TUBB4B—Pathogenic Escherichia coli infection—CDH1—uterine cancer	0.000545	0.00774	CbGpPWpGaD
Albendazole—Vomiting—Dactinomycin—uterine cancer	0.000545	0.00427	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000541	0.00424	CcSEcCtD
Albendazole—Rash—Dactinomycin—uterine cancer	0.000541	0.00424	CcSEcCtD
Albendazole—Pancytopenia—Doxorubicin—uterine cancer	0.000538	0.00421	CcSEcCtD
Albendazole—Neutropenia—Doxorubicin—uterine cancer	0.000529	0.00415	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—NDC80—uterine cancer	0.000521	0.0074	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—TSPYL2—uterine cancer	0.000519	0.00736	CbGpPWpGaD
Albendazole—Hepatobiliary disease—Epirubicin—uterine cancer	0.000516	0.00404	CcSEcCtD
Albendazole—Nausea—Dactinomycin—uterine cancer	0.000509	0.00399	CcSEcCtD
Albendazole—Agranulocytosis—Epirubicin—uterine cancer	0.000509	0.00399	CcSEcCtD
Albendazole—Gastrointestinal pain—Etoposide—uterine cancer	0.000508	0.00398	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.0005	0.00392	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000496	0.00704	CbGpPWpGaD
Albendazole—CYP1A1—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000495	0.00702	CbGpPWpGaD
Albendazole—Urticaria—Etoposide—uterine cancer	0.000493	0.00386	CcSEcCtD
Albendazole—Body temperature increased—Etoposide—uterine cancer	0.000491	0.00385	CcSEcCtD
Albendazole—Abdominal pain—Etoposide—uterine cancer	0.000491	0.00385	CcSEcCtD
Albendazole—Hepatitis—Epirubicin—uterine cancer	0.00049	0.00384	CcSEcCtD
Albendazole—Urinary tract disorder—Epirubicin—uterine cancer	0.000484	0.00379	CcSEcCtD
Albendazole—CYP1A2—Estrogen Receptor Pathway—ESR1—uterine cancer	0.000482	0.00685	CbGpPWpGaD
Albendazole—Urethral disorder—Epirubicin—uterine cancer	0.00048	0.00376	CcSEcCtD
Albendazole—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000477	0.00374	CcSEcCtD
Albendazole—Agranulocytosis—Doxorubicin—uterine cancer	0.000471	0.00369	CcSEcCtD
Albendazole—TUBA1A—p73 transcription factor network—EP300—uterine cancer	0.000464	0.00659	CbGpPWpGaD
Albendazole—Erythema multiforme—Epirubicin—uterine cancer	0.000463	0.00363	CcSEcCtD
Albendazole—Hypersensitivity—Etoposide—uterine cancer	0.000457	0.00358	CcSEcCtD
Albendazole—Hepatitis—Doxorubicin—uterine cancer	0.000453	0.00355	CcSEcCtD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000453	0.00643	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MLH3—uterine cancer	0.00045	0.00639	CbGpPWpGaD
Albendazole—Urinary tract disorder—Doxorubicin—uterine cancer	0.000447	0.00351	CcSEcCtD
Albendazole—CYP1A1—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000447	0.00634	CbGpPWpGaD
Albendazole—Urethral disorder—Doxorubicin—uterine cancer	0.000444	0.00348	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—POLD1—uterine cancer	0.000443	0.00629	CbGpPWpGaD
Albendazole—Immune system disorder—Epirubicin—uterine cancer	0.000442	0.00347	CcSEcCtD
Albendazole—Alopecia—Epirubicin—uterine cancer	0.000433	0.00339	CcSEcCtD
Albendazole—Erythema multiforme—Doxorubicin—uterine cancer	0.000428	0.00336	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000413	0.00587	CbGpPWpGaD
Albendazole—CYP1A1—Tryptophan metabolism—CYP19A1—uterine cancer	0.000412	0.00585	CbGpPWpGaD
Albendazole—Dizziness—Etoposide—uterine cancer	0.00041	0.00322	CcSEcCtD
Albendazole—Immune system disorder—Doxorubicin—uterine cancer	0.000409	0.00321	CcSEcCtD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—uterine cancer	0.000403	0.00572	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—uterine cancer	0.000403	0.00572	CbGpPWpGaD
Albendazole—TUBB4B—Pathogenic Escherichia coli infection—CTNNB1—uterine cancer	0.000403	0.00572	CbGpPWpGaD
Albendazole—Alopecia—Doxorubicin—uterine cancer	0.0004	0.00314	CcSEcCtD
Albendazole—Vomiting—Etoposide—uterine cancer	0.000395	0.00309	CcSEcCtD
Albendazole—Rash—Etoposide—uterine cancer	0.000391	0.00307	CcSEcCtD
Albendazole—Dermatitis—Etoposide—uterine cancer	0.000391	0.00306	CcSEcCtD
Albendazole—Headache—Etoposide—uterine cancer	0.000389	0.00305	CcSEcCtD
Albendazole—TUBA1A—Metabolism of proteins—INHBA—uterine cancer	0.000384	0.00545	CbGpPWpGaD
Albendazole—Vertigo—Epirubicin—uterine cancer	0.000383	0.003	CcSEcCtD
Albendazole—Leukopenia—Epirubicin—uterine cancer	0.000382	0.00299	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—RRM2—uterine cancer	0.000369	0.00524	CbGpPWpGaD
Albendazole—Nausea—Etoposide—uterine cancer	0.000369	0.00289	CcSEcCtD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000367	0.00521	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—MME—uterine cancer	0.000361	0.00512	CbGpPWpGaD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.00036	0.00282	CcSEcCtD
Albendazole—ABCB1—lymph node—uterine cancer	0.000359	0.0028	CbGeAlD
Albendazole—Vertigo—Doxorubicin—uterine cancer	0.000354	0.00278	CcSEcCtD
Albendazole—Leukopenia—Doxorubicin—uterine cancer	0.000353	0.00277	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—NDC80—uterine cancer	0.000352	0.005	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000349	0.00496	CbGpPWpGaD
Albendazole—TUBA1A—G2/M Transition—EP300—uterine cancer	0.000348	0.00495	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—AKR1B10—uterine cancer	0.000346	0.00491	CbGpPWpGaD
Albendazole—TUBA1A—Mitotic G2-G2/M phases—EP300—uterine cancer	0.000344	0.00488	CbGpPWpGaD
Albendazole—Thrombocytopenia—Epirubicin—uterine cancer	0.000341	0.00267	CcSEcCtD
Albendazole—Skin disorder—Epirubicin—uterine cancer	0.000338	0.00265	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000333	0.00261	CcSEcCtD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000333	0.00473	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.000332	0.00471	CbGpPWpGaD
Albendazole—CYP1A1—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000329	0.00467	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—MLH1—uterine cancer	0.000328	0.00466	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—AKR1B1—uterine cancer	0.000321	0.00456	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000315	0.00448	CbGpPWpGaD
Albendazole—Thrombocytopenia—Doxorubicin—uterine cancer	0.000315	0.00247	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle—NDC80—uterine cancer	0.000315	0.00447	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—ABCC9—uterine cancer	0.000313	0.00444	CbGpPWpGaD
Albendazole—Skin disorder—Doxorubicin—uterine cancer	0.000313	0.00245	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—POLD1—uterine cancer	0.000299	0.00425	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—YWHAE—uterine cancer	0.000297	0.00421	CbGpPWpGaD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000289	0.0041	CbGpPWpGaD
Albendazole—CYP1A2—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000285	0.00405	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Epirubicin—uterine cancer	0.000284	0.00223	CcSEcCtD
Albendazole—Urticaria—Epirubicin—uterine cancer	0.000276	0.00217	CcSEcCtD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000275	0.00391	CbGpPWpGaD
Albendazole—Abdominal pain—Epirubicin—uterine cancer	0.000275	0.00216	CcSEcCtD
Albendazole—Body temperature increased—Epirubicin—uterine cancer	0.000275	0.00216	CcSEcCtD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.00027	0.00383	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—POLD1—uterine cancer	0.000268	0.0038	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000263	0.00206	CcSEcCtD
Albendazole—CYP1A2—Tryptophan metabolism—CYP19A1—uterine cancer	0.000263	0.00373	CbGpPWpGaD
Albendazole—Hypersensitivity—Epirubicin—uterine cancer	0.000256	0.00201	CcSEcCtD
Albendazole—Urticaria—Doxorubicin—uterine cancer	0.000256	0.002	CcSEcCtD
Albendazole—Abdominal pain—Doxorubicin—uterine cancer	0.000254	0.00199	CcSEcCtD
Albendazole—Body temperature increased—Doxorubicin—uterine cancer	0.000254	0.00199	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—RRM2—uterine cancer	0.000249	0.00354	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.000249	0.00354	CbGpPWpGaD
Albendazole—Hypersensitivity—Doxorubicin—uterine cancer	0.000237	0.00186	CcSEcCtD
Albendazole—TUBA1A—Metabolism of proteins—FBXW7—uterine cancer	0.000237	0.00337	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000236	0.00335	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000234	0.00332	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—INHBA—uterine cancer	0.000232	0.00329	CbGpPWpGaD
Albendazole—Dizziness—Epirubicin—uterine cancer	0.00023	0.0018	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle—RRM2—uterine cancer	0.000223	0.00317	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN2B—uterine cancer	0.000223	0.00316	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000223	0.00316	CbGpPWpGaD
Albendazole—Vomiting—Epirubicin—uterine cancer	0.000221	0.00173	CcSEcCtD
Albendazole—CYP1A2—Metapathway biotransformation—AKR1B10—uterine cancer	0.00022	0.00313	CbGpPWpGaD
Albendazole—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00022	0.00312	CbGpPWpGaD
Albendazole—Rash—Epirubicin—uterine cancer	0.000219	0.00172	CcSEcCtD
Albendazole—Dermatitis—Epirubicin—uterine cancer	0.000219	0.00172	CcSEcCtD
Albendazole—Headache—Epirubicin—uterine cancer	0.000218	0.00171	CcSEcCtD
Albendazole—TUBB4B—Metabolism of proteins—MME—uterine cancer	0.000218	0.00309	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.000215	0.00305	CbGpPWpGaD
Albendazole—Dizziness—Doxorubicin—uterine cancer	0.000213	0.00167	CcSEcCtD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000212	0.00302	CbGpPWpGaD
Albendazole—TUBB4B—G2/M Transition—EP300—uterine cancer	0.00021	0.00299	CbGpPWpGaD
Albendazole—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00021	0.00298	CbGpPWpGaD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—EP300—uterine cancer	0.000207	0.00295	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—GPX3—uterine cancer	0.000207	0.00294	CbGpPWpGaD
Albendazole—Nausea—Epirubicin—uterine cancer	0.000207	0.00162	CcSEcCtD
Albendazole—CYP1A2—Metapathway biotransformation—AKR1B1—uterine cancer	0.000205	0.00291	CbGpPWpGaD
Albendazole—Vomiting—Doxorubicin—uterine cancer	0.000205	0.0016	CcSEcCtD
Albendazole—Rash—Doxorubicin—uterine cancer	0.000203	0.00159	CcSEcCtD
Albendazole—Dermatitis—Doxorubicin—uterine cancer	0.000203	0.00159	CcSEcCtD
Albendazole—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	0.000203	0.00288	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	0.000202	0.00287	CbGpPWpGaD
Albendazole—Headache—Doxorubicin—uterine cancer	0.000202	0.00158	CcSEcCtD
Albendazole—TUBB4B—Cell Cycle, Mitotic—YWHAE—uterine cancer	0.0002	0.00284	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—MLH1—uterine cancer	0.000198	0.00281	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000195	0.00277	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—CYP11A1—uterine cancer	0.000195	0.00277	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000192	0.00273	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—BIRC5—uterine cancer	0.000192	0.00273	CbGpPWpGaD
Albendazole—Nausea—Doxorubicin—uterine cancer	0.000191	0.0015	CcSEcCtD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000187	0.00266	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000187	0.00266	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000182	0.00258	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000181	0.00256	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—YWHAE—uterine cancer	0.000179	0.00254	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—uterine cancer	0.000175	0.00249	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000173	0.00246	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000172	0.00244	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	0.00017	0.00242	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000164	0.00233	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000164	0.00233	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000164	0.00233	CbGpPWpGaD
Albendazole—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000162	0.0023	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	0.000158	0.00225	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	0.000156	0.00221	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	0.000154	0.00218	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2B—uterine cancer	0.00015	0.00214	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—AKR1C1—uterine cancer	0.00015	0.00214	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—CYP19A1—uterine cancer	0.000143	0.00204	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—FBXW7—uterine cancer	0.000143	0.00203	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN2A—uterine cancer	0.000143	0.00202	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	0.000142	0.00202	CbGpPWpGaD
Albendazole—CYP1A1—Metapathway biotransformation—CYP19A1—uterine cancer	0.000141	0.00201	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN2B—uterine cancer	0.000135	0.00191	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	0.000133	0.00189	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	0.000132	0.00188	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—GPX3—uterine cancer	0.000132	0.00188	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—BIRC5—uterine cancer	0.00013	0.00184	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN2A—uterine cancer	0.000127	0.00181	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDKN1B—uterine cancer	0.000126	0.00179	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000125	0.00178	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000125	0.00178	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000125	0.00178	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—CYP11A1—uterine cancer	0.000124	0.00177	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—CYP11A1—uterine cancer	0.000123	0.00174	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CCL2—uterine cancer	0.000122	0.00173	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—uterine cancer	0.000119	0.00169	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—uterine cancer	0.000119	0.00169	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—BIRC5—uterine cancer	0.000116	0.00165	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	0.000116	0.00165	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.000116	0.00165	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—AKR1C3—uterine cancer	0.000116	0.00164	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CDKN1B—uterine cancer	0.000113	0.0016	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	0.000112	0.0016	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—EP300—uterine cancer	0.000111	0.00157	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.00011	0.00157	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	0.000105	0.0015	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—uterine cancer	0.000105	0.00149	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—EP300—uterine cancer	0.000105	0.00149	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	0.000102	0.00145	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—CXCL8—uterine cancer	9.93e-05	0.00141	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—uterine cancer	9.92e-05	0.00141	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—EP300—uterine cancer	9.91e-05	0.00141	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	9.83e-05	0.0014	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—uterine cancer	9.8e-05	0.00139	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CXCL8—uterine cancer	9.63e-05	0.00137	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	9.6e-05	0.00136	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	9.5e-05	0.00135	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	9.46e-05	0.00134	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	9.45e-05	0.00134	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	9.31e-05	0.00132	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	9.18e-05	0.0013	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—CYP19A1—uterine cancer	9.15e-05	0.0013	CbGpPWpGaD
Albendazole—CYP1A2—Metapathway biotransformation—CYP19A1—uterine cancer	9.02e-05	0.00128	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	8.94e-05	0.00127	CbGpPWpGaD
Albendazole—TUBA1A—Metabolism of proteins—CTNNB1—uterine cancer	8.89e-05	0.00126	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN2A—uterine cancer	8.61e-05	0.00122	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—uterine cancer	8.43e-05	0.0012	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—EP300—uterine cancer	8.18e-05	0.00116	CbGpPWpGaD
Albendazole—ABCB1—Allograft Rejection—VEGFA—uterine cancer	8.06e-05	0.00114	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—uterine cancer	8e-05	0.00114	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	7.98e-05	0.00113	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	7.98e-05	0.00113	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NDUFB11—uterine cancer	7.71e-05	0.00109	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SRD5A2—uterine cancer	7.71e-05	0.00109	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN2A—uterine cancer	7.69e-05	0.00109	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDKN1B—uterine cancer	7.62e-05	0.00108	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	7.49e-05	0.00106	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CCL2—uterine cancer	7.36e-05	0.00104	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—uterine cancer	7.17e-05	0.00102	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TP53—uterine cancer	7.09e-05	0.00101	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.07e-05	0.001	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	7.06e-05	0.001	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	7.04e-05	0.000999	CbGpPWpGaD
Albendazole—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	6.96e-05	0.000989	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDKN1B—uterine cancer	6.81e-05	0.000968	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—EP300—uterine cancer	6.69e-05	0.00095	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NDUFB11—uterine cancer	6.16e-05	0.000874	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SRD5A2—uterine cancer	6.16e-05	0.000874	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—EP300—uterine cancer	5.98e-05	0.00085	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	5.94e-05	0.000843	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	5.86e-05	0.000832	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CXCL8—uterine cancer	5.82e-05	0.000826	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—STAR—uterine cancer	5.57e-05	0.000791	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKR1B1—uterine cancer	5.57e-05	0.000791	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—uterine cancer	5.51e-05	0.000783	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.51e-05	0.000782	CbGpPWpGaD
Albendazole—TUBB4B—Metabolism of proteins—CTNNB1—uterine cancer	5.37e-05	0.000762	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	5.17e-05	0.000733	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NDUFB11—uterine cancer	4.92e-05	0.000698	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SRD5A2—uterine cancer	4.92e-05	0.000698	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	4.78e-05	0.000679	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	4.77e-05	0.000678	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	4.52e-05	0.000642	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	4.51e-05	0.00064	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—STAR—uterine cancer	4.45e-05	0.000632	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKR1B1—uterine cancer	4.45e-05	0.000632	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	4.4e-05	0.000625	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—POLD1—uterine cancer	4.37e-05	0.000621	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TP53—uterine cancer	4.28e-05	0.000608	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	4.2e-05	0.000596	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKR1C1—uterine cancer	4.09e-05	0.000581	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.98e-05	0.000565	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SRD5A2—uterine cancer	3.79e-05	0.000539	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NDUFB11—uterine cancer	3.79e-05	0.000539	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—RRM2—uterine cancer	3.65e-05	0.000518	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—STAR—uterine cancer	3.55e-05	0.000505	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKR1B1—uterine cancer	3.55e-05	0.000505	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—DCN—uterine cancer	3.54e-05	0.000503	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	3.51e-05	0.000499	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—POLD1—uterine cancer	3.49e-05	0.000496	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	3.38e-05	0.00048	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP11A1—uterine cancer	3.33e-05	0.000473	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKR1C1—uterine cancer	3.27e-05	0.000464	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKR1C3—uterine cancer	3.15e-05	0.000447	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	3.11e-05	0.000441	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	3.01e-05	0.000427	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—RRM2—uterine cancer	2.91e-05	0.000413	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—DCN—uterine cancer	2.83e-05	0.000401	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—POLD1—uterine cancer	2.79e-05	0.000396	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—STAR—uterine cancer	2.74e-05	0.000389	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKR1B1—uterine cancer	2.74e-05	0.000389	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP11A1—uterine cancer	2.66e-05	0.000378	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKR1C1—uterine cancer	2.61e-05	0.00037	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.54e-05	0.00036	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKR1C3—uterine cancer	2.52e-05	0.000357	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CYP19A1—uterine cancer	2.45e-05	0.000348	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—STK11—uterine cancer	2.45e-05	0.000348	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—RRM2—uterine cancer	2.32e-05	0.00033	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.3e-05	0.000327	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—DCN—uterine cancer	2.26e-05	0.00032	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.2e-05	0.000312	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—POLD1—uterine cancer	2.15e-05	0.000306	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP11A1—uterine cancer	2.13e-05	0.000302	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.01e-05	0.000286	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKR1C3—uterine cancer	2.01e-05	0.000285	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—STK11—uterine cancer	1.96e-05	0.000278	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CYP19A1—uterine cancer	1.96e-05	0.000278	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—MTHFR—uterine cancer	1.84e-05	0.000262	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—RRM2—uterine cancer	1.79e-05	0.000255	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—DCN—uterine cancer	1.74e-05	0.000247	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP11A1—uterine cancer	1.64e-05	0.000233	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.62e-05	0.000231	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—STK11—uterine cancer	1.56e-05	0.000222	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CYP19A1—uterine cancer	1.56e-05	0.000222	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKR1C3—uterine cancer	1.55e-05	0.00022	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—MTHFR—uterine cancer	1.47e-05	0.000209	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.47e-05	0.000208	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.4e-05	0.000199	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—STK11—uterine cancer	1.21e-05	0.000171	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.21e-05	0.000171	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—MTHFR—uterine cancer	1.18e-05	0.000167	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.04e-05	0.000147	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTEN—uterine cancer	1.03e-05	0.000146	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—EP300—uterine cancer	9.78e-06	0.000139	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—MTHFR—uterine cancer	9.07e-06	0.000129	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTEN—uterine cancer	8.19e-06	0.000116	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—EP300—uterine cancer	7.81e-06	0.000111	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PIK3CA—uterine cancer	7.24e-06	0.000103	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTEN—uterine cancer	6.54e-06	9.29e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—EP300—uterine cancer	6.24e-06	8.85e-05	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKT1—uterine cancer	5.91e-06	8.39e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PIK3CA—uterine cancer	5.78e-06	8.21e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTEN—uterine cancer	5.05e-06	7.17e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—EP300—uterine cancer	4.81e-06	6.83e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKT1—uterine cancer	4.72e-06	6.7e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PIK3CA—uterine cancer	4.61e-06	6.55e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKT1—uterine cancer	3.77e-06	5.35e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PIK3CA—uterine cancer	3.56e-06	5.06e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKT1—uterine cancer	2.91e-06	4.13e-05	CbGpPWpGaD
